Pharmaceutical

AbbVie and Tentarix enter biologic development deal

AbbVie has signed an agreement with Tentarix Biotherapeutics to discover and develop biologic candidates in oncology and immunology.

Feb 24, 2024 - 18:00
AbbVie and Tentarix enter biologic development deal
AbbVie has signed an agreement with Tentarix Biotherapeutics to discover and develop biologic candidates in oncology and immunology.
Read the original article

Tags:

Previous Article

AstraZeneca completes Gracell Biotechnologies acquisition for $1.2bn

Next Article

AstraZeneca’s Tagrisso-Chemo Combination Bags FDA Approval

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

New nasal spray to reverse fentanyl and other opioid overdoses gets FDA approval

New nasal spray to reverse fentanyl and other opioid ov...

May 23, 2023

Bio-Thera and Biomm enter licensing deal for ustekinumab biosimilar

Bio-Thera and Biomm enter licensing deal for ustekinuma...

Jun 19, 2023

Vinod Khosla’s bold AI prediction, digital therapeutics trial updates, & funding for AI in pharma

Vinod Khosla’s bold AI prediction, digital therapeutics...

May 5, 2023